Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lidocaine + epinephrine + dexamethasone
- Development stage
- Unknown
- Lead developer
- Isfahan University of Medical Sciences
- Modality
- Small Molecules
- Administration
- Local Injection
01
Overview
This drug combination consists of the local anesthetic lidocaine, the vasoconstrictor epinephrine, and the synthetic glucocorticoid dexamethasone. It is being investigated by the **Isfahan University of Medical Sciences** as an enhanced anesthetic solution for inferior alveolar nerve blocks (IANB) in patients suffering from **symptomatic irreversible pulpitis**. In the presence of pulpal inflammation, standard local anesthetics like lidocaine often fail due to altered tissue pH and inflammatory sensitization of nerve fibers. The addition of dexamethasone, a potent anti-inflammatory agent, is intended to improve the success rate of the anesthetic block by reducing local inflammation and potentially modulating nerve excitability.
- Other names
- lidocaine/epinephrine/dexamethasone combinationLidocaine/Dexamethasone for IANB
02
Targets
NaV (Voltage-gated sodium channels)ADRA1A (α1A)GR (Glucocorticoid receptor)ADRB1 (β1)
Beyond the preview
Go deeper on lidocaine + epinephrine + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lidocaine + epinephrine + dexamethasone.